Indications & Dose:

Indications

Indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic diseas

Dosage

Orally with food in combination with letrozole

Recommended starting dose: 125 mg once daily taken with food for 21 days followed by 7 days off treatment.

Contraindications:

-

Cautions:

-

Precautions:

-

Interaction:

-

Warnings:

WARNINGS AND PRECAUTIONs

- Hematologic, Neutropenia may occur. Monitor complete blood count prior to start of therapy and at the beginning of each cycle, as well as on Day 14 of the first two cycles and as clinically indicated

- Infections, Monitor for signs and symptoms and withhold dosing as appropriate

Embryo-Fetal Toxicity, Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception

Adverse Effects:

-

Lactations:

-

Special Precautions:

-

Counselling:

-

Side Effects Or Adverse Reactions:

Most common adverse reactions neutropenia, leukopenia, fatigue, anemia, upper respiratory infection, nausea, stomatitis, alopecia, diarrhea, thrombocytopenia, decreased appetite, vomiting, asthenia, peripheral neuropathy and epistaxis

Patient And Carer Advice:

-